Clinical Trial Detail

NCT ID NCT03451084
Title A Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Aslan Pharmaceuticals
Indications

acute myeloid leukemia

Therapies

ASLAN003

Age Groups: adult senior

No variant requirements are available.